NORTEC Pharma as part of FREWITT Group

At the end of January this year, there were changes in the ownership of our company, the majority shareholder of Nortec Pharma became the Swiss company Frewitt.

Frewitt Fabrique de Machines SA Switzerland is a leader in the development of bulk material processing processes and the production of top quality grinding equipment.

Since 1946, Frewitt has built a solid reputation as a supplier of high-quality products, always putting the optimization of process solutions first by providing state-of-the-art systems for grinding, sieving, homogenizing, deagglomerating, transporting, dosing and filling powders, granulates and suspensions of all types.

Considering the complementarity of the products of both companies and the long-term cooperation so far, we believe that this synergy will translate into safe and stable planning of the future of Nortec Pharma and Frewitt.

Antoine Virdis, CEO of Frewitt explained: “This acquisition represents an important milestone in Frewitt’s development. It demonstrates our commitment to innovation and our determination to strengthen our offer of ready-made solutions, our services and our proximity to our customers, while strengthening our position as one of the market leaders.”

Paweł Chrzanowski, CEO of Nortec Pharma stated that “the combined strengths of Frewitt and Nortec will strengthen the company’s growth and development, benefiting from an expanded product range and a global sales network.”

For the management of both companies, this acquisition is more than just a simple transaction. It is a combination of two cultures, two histories, two technology-driven teams that share the same values ​​and ambitions. Both parties are convinced that this union will create extraordinary synergies, a catalyst for growth, while providing greater benefits to customers and ensuring continued success in the years to come.

“Together we are starting to write the next chapter in our long history, marked by innovation, growth and a renewed focus on our customers. We will continue to invest in our people, our technology, our infrastructure and our core values ​​to remain at the forefront of our industry,” concluded Antoine Virdis.

The changes in the company structure have not affected the change of name, registration data or address of Nortec Pharma. We work in the same composition and Paweł Chrzanowski remains the CEO of the Company.